NO20011352L - Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav - Google Patents

Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Info

Publication number
NO20011352L
NO20011352L NO20011352A NO20011352A NO20011352L NO 20011352 L NO20011352 L NO 20011352L NO 20011352 A NO20011352 A NO 20011352A NO 20011352 A NO20011352 A NO 20011352A NO 20011352 L NO20011352 L NO 20011352L
Authority
NO
Norway
Prior art keywords
inhibitor
combination
treating atherosclerosis
pravastatin
employing
Prior art date
Application number
NO20011352A
Other languages
English (en)
Other versions
NO20011352D0 (no
Inventor
Jeffrey A Robl
Rex A Parker
Scott A Biller
Haris Jamil
Bruce L Jacobson
Krishna Kodukula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011352(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20011352D0 publication Critical patent/NO20011352D0/no
Publication of NO20011352L publication Critical patent/NO20011352L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
NO20011352A 1998-09-17 2001-03-16 Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav NO20011352L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17
PCT/US1999/021069 WO2000015230A1 (en) 1998-09-17 1999-09-13 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (2)

Publication Number Publication Date
NO20011352D0 NO20011352D0 (no) 2001-03-16
NO20011352L true NO20011352L (no) 2001-05-11

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20011351A NO20011351L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
NO20011352A NO20011352L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20011351A NO20011351L (no) 1998-09-17 2001-03-16 Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav

Country Status (30)

Country Link
US (1) US20020035064A1 (no)
EP (2) EP1121129B1 (no)
JP (2) JP2002524518A (no)
KR (2) KR20010075150A (no)
CN (2) CN1319012A (no)
AT (1) ATE406898T1 (no)
AU (2) AU754488B2 (no)
BG (2) BG105431A (no)
BR (2) BR9913831A (no)
CA (2) CA2344300A1 (no)
CO (2) CO5130026A1 (no)
CZ (2) CZ2001964A3 (no)
DE (1) DE69939481D1 (no)
EE (2) EE04356B1 (no)
ES (1) ES2311306T3 (no)
GE (2) GEP20033044B (no)
HU (2) HUP0104108A2 (no)
ID (2) ID28450A (no)
IL (2) IL141785A0 (no)
LT (2) LT4870B (no)
LV (2) LV12687B (no)
NO (2) NO20011351L (no)
NZ (2) NZ510207A (no)
PE (2) PE20001047A1 (no)
PL (2) PL346661A1 (no)
SK (1) SK3202001A3 (no)
TR (2) TR200100773T2 (no)
UY (2) UY25714A1 (no)
WO (2) WO2000015229A1 (no)
ZA (2) ZA200207433B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
CA2361335A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2004501066A (ja) 2000-01-28 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法
HUP0500543A2 (hu) * 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
EP1414461A4 (en) 2001-07-13 2005-10-26 Bristol Myers Squibb Co PYRAZINONE INHIBITORS OF FATTY ACID BINDING PROTEIN AND METHOD
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
WO2004084890A1 (en) * 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
MX2007009888A (es) 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
CN107149679B (zh) * 2009-03-05 2021-03-02 哈佛学院董事会 分泌的aP2及其抑制方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja) * 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
WO2016176656A2 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
CA3026521A1 (en) * 2016-06-27 2018-01-04 President And Fellows Of Harvard College Compounds useful to treat metabolic disorders
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (no) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
NZ224733A (en) 1987-05-22 1990-12-21 Squibb & Sons Inc Organophosphorus hmg-coa reductase inhibitors; intermediates and compositions thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
PT736018E (pt) * 1993-12-20 2000-10-31 Fujisawa Pharmaceutical Co Derivados de 4,5-diariloxazol
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
TR200100773T2 (tr) 2001-07-23
EE200100154A (et) 2002-12-16
ID27833A (id) 2001-04-26
EP1121129A1 (en) 2001-08-08
LV12687A (en) 2001-07-20
EP1121129A4 (en) 2002-10-16
EP1113801A4 (en) 2002-10-02
AU755563B2 (en) 2002-12-12
CA2344309A1 (en) 2000-03-23
AU6387799A (en) 2000-04-03
ID28450A (id) 2001-05-24
ES2311306T3 (es) 2009-02-01
CO5130025A1 (es) 2002-02-27
IL141785A0 (en) 2002-03-10
US20020035064A1 (en) 2002-03-21
CN1319012A (zh) 2001-10-24
UY25713A1 (es) 2001-08-27
BG105432A (en) 2001-12-29
UY25714A1 (es) 2001-08-27
GEP20033045B (en) 2003-08-25
NO20011351L (no) 2001-05-11
LT2001022A (en) 2001-08-27
SK3202001A3 (en) 2002-04-04
BG105431A (en) 2001-12-29
CZ2001964A3 (cs) 2002-01-16
LT2001023A (en) 2001-08-27
GEP20033044B (en) 2003-08-25
PL346660A1 (en) 2002-02-25
ATE406898T1 (de) 2008-09-15
JP2002524517A (ja) 2002-08-06
KR20010079842A (ko) 2001-08-22
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
CZ2001965A3 (cs) 2002-02-13
NO20011351D0 (no) 2001-03-16
EP1121129B1 (en) 2008-09-03
PE20001047A1 (es) 2000-12-24
NZ510207A (en) 2003-08-29
EP1113801A1 (en) 2001-07-11
HUP0104240A2 (hu) 2002-03-28
EE200100155A (et) 2002-08-15
EE04356B1 (et) 2004-10-15
IL141786A0 (en) 2002-03-10
NO20011352D0 (no) 2001-03-16
TR200100774T2 (tr) 2001-12-21
NZ510209A (en) 2003-07-25
CN1317970A (zh) 2001-10-17
PE20001056A1 (es) 2000-12-24
BR9913831A (pt) 2001-05-29
ZA200207433B (en) 2003-10-27
CA2344300A1 (en) 2000-03-23
AU754488B2 (en) 2002-11-14
JP2002524518A (ja) 2002-08-06
KR20010075150A (ko) 2001-08-09
PL346661A1 (en) 2002-02-25
CO5130026A1 (es) 2002-02-27
HUP0104108A2 (hu) 2002-03-28
LV12687B (lv) 2001-10-20
LT4870B (lt) 2001-12-27
LV12686A (en) 2001-07-20
BR9913833A (pt) 2001-05-29
ZA200207430B (en) 2003-09-16
WO2000015230A1 (en) 2000-03-23
WO2000015229A1 (en) 2000-03-23
DE69939481D1 (de) 2008-10-16
AU6143799A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
NO20011352D0 (no) FremgangsmÕte for behandling av aterosklerose ved anvendelse av en AP2 inhibitor og kombinasjon derav
NO20012317L (no) Fremgangsmåte for å behandle, forhindre og redusere risikoen for at Alzheimers sykdom oppstår ved å bruke en HMG COAreduktaseinhibitor
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
CA2249446A1 (en) Irreversible inhibitors of tyrosine kinases
AU1022795A (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
NL970034I2 (nl) Trans-6-Ä2-(3- of 4-carbonamido-gesubstitueerd pyrrool-1-y)alkylÜ-4-hydroxypyran-2-on als remmers van cholesterolsynthese.
DE69528528D1 (de) Thrombin-inhibitoren
ES2172657T3 (es) Inhibidores de trombina.
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
NO981578D0 (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
MY140504A (en) Statin-mmp inhibitor combinations
AU2177701A (en) Use of hmg-coa reductase inhibitors for treating seborrhea
BR0112460A (pt) Método para tratamento de sépsis
IT1255470B (it) Composti attivi come inibitori dell&#39;enzima hmg-coa reduttasi
DE69617433T2 (de) Hemmstoff für ribonukleotid-reduktase von herpesviren
NO923862L (no) Inhibitorer for hmg-coa-reduktase
MX9602577A (es) Tratamiento de arterioesclerosis y xantoma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application